Cardiff Oncology Inc. (NASDAQ: CRDF) presented preclinical data on its PLK1 inhibitor onvansertib combined with trastuzumab deruxtecan at the American ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA